Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy
Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy
复制标题
DOI:
10.2337/diacare.26.9.2632
复制
发表时间:
2003-09-01
期刊:
影响因子:
16.2
通讯作者:
Jerums, G
中科院分区:
文献类型:
--
作者:
Gilbert, RE;Akdeniz, A;Jerums, G
genesis of tubulointerstitial disease that characterizes proteinuric renal disease. In this cross-sectional study, we sought to examine the urinary excretion of the profibrotic cytokine connective tissue growth factor (CTGF) in type I diabetic patients with incipient and overt diabetic nephropathy.RESEARCH DESIGN AND METHODS - We recruited 31 subjects with type I diabetes from a hospital diabetes outpatient clinic. Of these, 10 subjects were normoalbuminuric, 8 were microalbuminuric and not receiving ACE inhibitor treatment, and 13 were macroalbuminuric, 8 of whom were receiving ACE inhibitor treatment. Urinary CTGF NH2-terminal fragment (CTGF-N) was determined by enzyme-linked immunosorbent assay and expressed relative to urinary creatinine.RESULTS - Urinary CTGF-N was closely correlated with the degree of albuminuria (r = 0.76, P < 0.001). In comparison with normoalbuminuric subjects, urinary CTGF-N was increased 10- and 100-fold in micro- and untreated macroalbuminuric subjects, respectively (CTGF-N-to-creatinine ratio: normoalbuminuria 0.23 X/÷ 1.3 ng/mg, microalbuminuria 2.1 X/÷ 1.7 ng/mg, untreated macroalbuminuria 203 X/÷ 3.8 ng/mg, and geometric mean X/÷ tolerance factor; P < 0.05 for normoalbuminuria versus microalbuminuria, P < 0.001 for microalbuminuria versus macroalbuminuria). Urinary CTGF-N was lower (